These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 27894611)

  • 1. The Threshold Theory for Parkinson's Disease.
    Engelender S; Isacson O
    Trends Neurosci; 2017 Jan; 40(1):4-14. PubMed ID: 27894611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cortical Pathogenic Theory of Parkinson's Disease.
    Foffani G; Obeso JA
    Neuron; 2018 Sep; 99(6):1116-1128. PubMed ID: 30236282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.
    Geibl FF; Henrich MT; Oertel WH
    J Neural Transm (Vienna); 2019 Apr; 126(4):377-396. PubMed ID: 30643975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's disease as a multisystem disorder.
    Klingelhoefer L; Reichmann H
    J Neural Transm (Vienna); 2017 Jun; 124(6):709-713. PubMed ID: 28155133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Causes and consequences of degeneration of the dorsal motor nucleus of the vagus nerve in Parkinson's disease.
    Greene JG
    Antioxid Redox Signal; 2014 Aug; 21(4):649-67. PubMed ID: 24597973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synaptic dysfunction in Parkinson's disease.
    Picconi B; Piccoli G; Calabresi P
    Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain-First versus Gut-First Parkinson's Disease: A Hypothesis.
    Borghammer P; Van Den Berge N
    J Parkinsons Dis; 2019; 9(s2):S281-S295. PubMed ID: 31498132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
    Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
    Coune PG; Bensadoun JC; Aebischer P; Schneider BL
    J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Parkinson's disease start in the gut?
    Lionnet A; Leclair-Visonneau L; Neunlist M; Murayama S; Takao M; Adler CH; Derkinderen P; Beach TG
    Acta Neuropathol; 2018 Jan; 135(1):1-12. PubMed ID: 29039141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats.
    Holmqvist S; Chutna O; Bousset L; Aldrin-Kirk P; Li W; Björklund T; Wang ZY; Roybon L; Melki R; Li JY
    Acta Neuropathol; 2014 Dec; 128(6):805-20. PubMed ID: 25296989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylcorynoline attenuates dopaminergic neuron degeneration and α-synuclein aggregation in animal models of Parkinson's disease.
    Fu RH; Wang YC; Chen CS; Tsai RT; Liu SP; Chang WL; Lin HL; Lu CH; Wei JR; Wang ZW; Shyu WC; Lin SZ
    Neuropharmacology; 2014 Jul; 82():108-20. PubMed ID: 23973292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of dopaminergic presynaptic function by [F-18] DOPA PET].
    Kato T
    Rinsho Shinkeigaku; 2007 Nov; 47(11):829-31. PubMed ID: 18210809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
    Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
    Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common pathophysiology affecting diabetic retinopathy and Parkinson's disease.
    Tian T; Li Z; Lu H
    Med Hypotheses; 2015 Oct; 85(4):397-8. PubMed ID: 26141638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence.
    Pellegrini C; Antonioli L; Colucci R; Ballabeni V; Barocelli E; Bernardini N; Blandizzi C; Fornai M
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1407-14. PubMed ID: 26499757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The gut-brain axis in Parkinson's disease: Possibilities for food-based therapies.
    Perez-Pardo P; Kliest T; Dodiya HB; Broersen LM; Garssen J; Keshavarzian A; Kraneveld AD
    Eur J Pharmacol; 2017 Dec; 817():86-95. PubMed ID: 28549787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-Synuclein is a pathological link and therapeutic target for Parkinson's disease and traumatic brain injury.
    Shahaduzzaman M; Acosta S; Bickford PC; Borlongan CV
    Med Hypotheses; 2013 Oct; 81(4):675-80. PubMed ID: 23920272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated.
    Bezard E; Gross CE; Brotchie JM
    Trends Neurosci; 2003 Apr; 26(4):215-21. PubMed ID: 12689773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysfunctional and compensatory synaptic plasticity in Parkinson's disease.
    Schroll H; Vitay J; Hamker FH
    Eur J Neurosci; 2014 Feb; 39(4):688-702. PubMed ID: 24313650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.